3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia
1
Interventions
Cyclophosphamide
414
Cytarabine
336
fludarabine phosphate
231
Rituximab
206
Methotrexate
198
fludarabine
196
venetoclax
174
Azacitidine
174
Busulfan
169
Filgrastim
145
Whole-Body Irradiation
143
Mycophenolic Acid
143
Peripheral Blood Stem Cell Transplantation
141
Tacrolimus
138
Etoposide
130
Vincristine
112
Melphalan
110
Dexamethasone
109
Cyclosporine
102
Granulocyte Colony-Stimulating Factor
100
Imatinib Mesylate
94
Antilymphocyte Serum
91
Daunorubicin
90
Radiotherapy
84
Decitabine
83
Dasatinib
76
Lenalidomide
75
Doxorubicin
70
Prednisone
68
Idarubicin
68
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Ranitidine
×
Other hematologic neoplasm
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts